Arcus Biosciences stock fell 3.13 percent on October 2

Published on 10/04/2026 at 20:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arcus Biosciences stock faces an October 20 casdatifan data event covering 121 late-line patients. Q2 revenue reached USD 41 million against USD 21.98 million expected.

RCUS, US03969F1093, Illustration mit AI erstellt.

Arcus Biosciences stock (ISIN US03969F1093) was last at USD 24.44 on the NYSE on October 2, 2026, down 3.13 percent from the prior session. The next company-specific milestone is an October 20 investor event focused on new casdatifan data across kidney cancer treatment settings.

October data puts casdatifan first

According to Business Wire on September 22, 2026, Arcus will present ARC-20 results on October 20, 2026. The program covers casdatifan alone and in combinations for first-line, second-line and late-line clear cell renal cell carcinoma.

The planned presentation includes data from 30 patients in first-line TKI-free combinations, 43 patients in the second-line casdatifan plus cabozantinib cohort and 121 patients in pooled late-line monotherapy cohorts. The company also expects PEAK-1 enrollment to finish by year-end 2026 and plans to initiate the Phase 3 PEAK-20 study in the fourth quarter of 2026, according to Business Wire.

Q2 revenue beat met cash pressure

In Q2 2026, Arcus generated USD 41 million in revenue and posted a GAAP net loss of USD 91 million, or USD 0.72 per share. The figures came from collaboration revenue and were reported in the earnings-call transcript carried by The Globe and Mail on October 2, 2026.

The revenue result exceeded the USD 21.98 million consensus estimate by USD 19.02 million, while the per-share loss was USD 0.17 better than the expected USD 0.89 loss, according to MarketBeat on October 3, 2026. The same earnings-call coverage put cash and marketable securities at USD 775 million on June 30, 2026, with management projecting a cash runway into the second half of 2028.

Consensus target stays above the quote

MarketBeat reported a Moderate Buy consensus from 13 analysts on October 3, 2026, with nine Buy ratings, three Holds and one Sell. The average 12-month price target was USD 38.30, meaning the price target lies 56.71 percent above the October 2 price of USD 24.44.

Wedbush reiterated an Outperform rating and a USD 43 price target on October 1, 2026, according to RTTNews. That view puts the price target 75.94 percent above the October 2 quote, but the valuation still depends heavily on clinical execution and future casdatifan data.

Stock remains below its yearly high

RCUS was last at USD 24.44 on the NYSE on October 2, 2026 at 4:00 p.m. ET, with a market capitalization of USD 3.1 billion and a 52-week range of USD 13.61 to USD 31.74. The quote was 22.99 percent below the 52-week high, leaving the October 20 data event as the next measurable test for the casdatifan thesis.